Inhibition of HDAC2 in a chemosensitive ovarian cancer cell line, PEO1, increased the efficacy of carboplatin treatment and increased γH2AX foci, and caused downregulation of phosphorylated BRCA1 [77]. Here, HDAC2 is linked to ovarian carcinoma.